Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis August 3, 2026
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights March 6, 2026
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis February 10, 2026
